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ABSTRACT
Introduction Fetal growth restriction (FGR) is a major
contributor to fetal and neonatal morbidity and mortality
with intrauterine, neonatal and lifelong complications. This
study explores maternal obstructive sleep apnoea (OSA) as
a potentially modifiable risk factor for FGR. We hypothesise
that, in pregnancies complicated by FGR, treating mothers
who have OSA using positive airway pressure (PAP) will
improve birth weight and neonatal outcomes.
Methods and analysis The Sleep Apnea and Fetal Growth
Restriction study is a prospective, block-randomised,
single-blinded, multicentre, pragmatic controlled trial. We
enrol pregnant women aged 18–50, between 22 and 31
weeks of gestation, with established FGR based on second
trimester ultrasound, who do not have other prespecified
known causes of FGR (such as congenital anomalies or
intrauterine infection). In stage 1, participants are screened
by questionnaire for OSA risk. If OSA risk is identified,
participants proceed to stage 2, where they undergo home
sleep apnoea testing. Participants are determined to have
OSA if they have an apnoea-hypopnoea index (AHI) ≥5 (if
the oxygen desaturation index (ODI) is also ≥5) or if they
have an AHI ≥10 (even if the ODI is <5). These participants
proceed to stage 3, where they are randomised to nightly
treatment with PAP or no PAP (standard care control),
which is maintained until delivery. The primary outcome
is unadjusted birth weight; secondary outcomes include
fetal growth velocity on ultrasound, enrolment-to-
delivery interval, gestational age at delivery, birth weight
corrected for gestational age, stillbirth, Apgar score, rate of
admission to higher levels of care (neonatal intensive care
unit or special care nursery) and length of neonatal stay.
These outcomes are compared between PAP and control
using intention-to-treat analysis.
Ethics and dissemination This study has been approved
by the Institutional Review Boards at Washington University
in St Louis, Missouri; Hadassah Hebrew University Medical
Center, Jerusalem; and the University of Rochester, New
York. Recruitment began in Washington University in
November 2019 but stopped from March to November

Strengths and limitations of this study
►► Sleep Apnea and Fetal Growth Restriction study is a

multicentre, pragmatic trial conducted in a tertiary
care setting.
►► Studying patients with both fetal growth restriction and home sleep apnoea testing-
diagnosed
obstructive sleep apnoea (OSA) increases the potential for benefit from the intervention but limits
generalisability.
►► The intervention is positive airway pressure, a
routine, safe and effective therapy for OSA in non-
pregnant populations.
►► While investigators and care providers are blinded to group allocation in stage 3, participants are
unblinded.
►► Positive findings will increase OSA awareness and
treatment in pregnancy.

2020 due to COVID-19. Recruitment began in Hadassah
Hebrew University in March 2021, and in the University
of Rochester in May 2021. Dissemination plans include
presentations at scientific conferences and scientific
publications.
Trial registration number NCT04084990.

BACKGROUND
Fetal growth restriction (FGR) affects up
to 10% of all pregnancies and is a major
contributor to fetal and neonatal morbidity
and mortality with intrauterine, neonatal
and lifelong complications.1 2 FGR is second
only to prematurity as a leading cause of
perinatal morbidity and mortality. Both FGR
and prematurity are independent risk factors
for the development of cognitive delay, poor
academic achievement and adult diseases
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accompanying maternal oxyhaemoglobin desaturation,27
while another found no association.28
Positive airway pressure (PAP) is a common and
effective treatment for OSA which acts by mechanically
splinting the upper airway with pressurised air to prevent
collapse. PAP delivered at a single pressure (continuous
PAP or CPAP) usually requires a sleep study to identify
optimal settings; it also cannot respond to changes in
upper airway function related to changes in habitus, body
position, sleep stage or other factors. In contrast, autotitrating PAP (aPAP) can detect upper airway resistance
and respond by adjusting the delivered pressure (within
a selected range). The delivered pressures from aPAP can
therefore be lower than from CPAP, which makes aPAP
more tolerable for most patients.29 We use aPAP as the
intervention for all patients in the Sleep Apnea and Fetal
Growth Restriction (SAFER) study. However, as much
of the medical literature is still based on CPAP rather
than aPAP, we use the generic term PAP throughout the
remainder of this manuscript.
PAP is a proven low-risk therapeutic intervention for
patients with OSA in the general, non-obstetric population. Multiple studies have shown that PAP use in patients
with OSA reduces the incidence of death from cardiac-
related complications including congestive heart failure,
coronary artery disease, arrhythmia and stroke,30–32 and
may improve outcomes related to diabetes.33 34 Small
studies of PAP in pregnant women with severe pre-
eclampsia and OSA diagnosed by PSG demonstrated
improved maternal haemodynamic profiles and cardiac
output35 36 although no obstetric or neonatal outcomes
were measured.
The hypothesis of the SAFER study is that, in pregnancies complicated by FGR where the mothers have been
diagnosed with OSA, maternal PAP therapy will improve
intrauterine fetal growth and birth weight, increase
randomisation-to-delivery interval and the gestational age
at delivery and improve neonatal well-being. Ultimately,
if PAP therapy is shown to improve intrauterine fetal
growth in pregnancies with OSA and FGR, obstetric practice would be expected to change. Such a finding would
lead to a clinical imperative to screen, diagnose and treat
OSA in pregnancy, particularly in the presence of FGR.
METHODS
Research design overview
The Human Research Protection Office at Washington
University School of Medicine in St Louis, Missouri, the
Research Subject Review Board at the University of Rochester, New York, and the Helsinki Committee for Ethics
in Research in Human Subjects in Hadassah Hebrew
University Medical Center, Jerusalem, Israel, all approved
the study. The choice of these sites was determined by the
location of the principal investigators involved in initiation of this study; however, all sites are academic, high-
risk obstetric, tertiary referral centres with large numbers
of pregnancies complicated by FGR. There is wide
Hincker A, et al. BMJ Open 2021;11:e049120. doi:10.1136/bmjopen-2021-049120
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such as obesity, type 2 diabetes mellitus, coronary artery
disease and stroke.3 There are many potential causes of
FGR, but in the absence of underlying genetic conditions, congenital anomalies or intrauterine infection,
FGR is typically due to impaired uteroplacental perfusion.2 4 Current assessment is based on repeated ultrasound assessments of fetal growth, antenatal testing
including non-
stress test and/or biophysical profile
(including electronic fetal heart rate monitoring) and
umbilical artery Doppler velocimetry.5 Intervention is
limited to antenatal steroid administration and interventional delivery when the risk of stillbirth is deemed too
high to continue the pregnancy. There is no intervention
currently available to improve uteroplacental blood flow
and fetal growth in utero, so there is often no alternative to interventional delivery.6 When the pregnancy is
remote from term, interventional delivery exposes an
already compromised fetus to additional complications of
prematurity, in particular to neonatal brain injury from
intraventricular haemorrhage.7 8
Pregnancy is associated with a higher incidence of sleep
disordered breathing (SDB), a group of chronic conditions involving recurrent episodic partial or complete
cessation of breathing throughout the night.9 Obstructive
sleep apnoea (OSA) is an increasingly common form of
SDB in both the general and pregnant population.10 OSA
is characterised by complete (apnoea) or incomplete
(hypopnoea) collapse of the upper airway during sleep
leading to recurrent episodic cessation or limitation of
normal breathing. This in turn leads to recurrent oxygen
desaturation and hypercapnia, frequent night-
time
arousals and excessive daytime sleepiness.11 12
OSA in pregnancy has been associated with poor
maternal-
fetal outcomes, including gestational hypertension, pre-
eclampsia, gestational diabetes, FGR,
low birth weight, preterm delivery and higher rates of
neonatal intensive care unit (NICU) admission.13–20
Patients with OSA are more likely to have negative
neonatal outcomes,21 and severe maternal morbidity
and mortality,17 regardless of their obesity status. The
relationship between severity of OSA in pregnancy and
adverse outcomes is an ongoing area of research.22
Unfortunately, because few pregnant women are
referred for polysomnography (PSG), it is likely that
OSA and other sleep disorders are underdiagnosed,23
with the OSA-related symptoms of snoring, disrupted
sleep and fatigue being frequently attributed to transient features of normal pregnancy.24
Recurrent apnoeic and hypopnoeic episodes are associated with intermittent oxygen desaturation and hypercapnia. Recurrent hypoxia leads to oxidative stress,
sympathetic activation and inflammation that may be
harmful to both the mother and her fetus.25 Acute hypercapnia in pregnant mice and rats has been shown to cause
acute placental hypoperfusion and acute fetal asphyxia.26
There is very little information about the effect of
these episodes on the human fetus. One small observational study demonstrated fetal heart rate decelerations
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geographic and demographic diversity between these
centres, which adds to the generalisability of the study.
The SAFER study detailed in this protocol adheres to the
Standard Protocol Items: Recommendations for Interventional Trials checklist,37 and lists the 24 items in the
WHO Trial Registration Data Set. The protocol version is
dated 5 February 2020. The SAFER study is a three-stage
trial that assesses pregnant patients with diagnosed FGR.
The overall flow of participants through the SAFER study
is shown in figure 1.
We enrol women with pregnancies complicated by
FGR between 22 and 31 weeks of gestation. Stage 1 is
Hincker A, et al. BMJ Open 2021;11:e049120. doi:10.1136/bmjopen-2021-049120

a brief telephone or in-person questionnaire to identify
which of these pregnant women are at elevated risk for
OSA; these women are then recruited into stage 2. Stage
2 is a prospective observational study using home sleep
apnoea testing (HSAT) to confirm the diagnosis of OSA.
Participants meeting OSA diagnostic criteria progress to
stage 3. Stage 3 is a pragmatic randomised clinical trial
of PAP as the intervention, versus a control group of
standard care which does not include PAP. The primary
outcome of stage 3 is birth weight; secondary outcomes
include fetal growth velocity on ultrasound, birth weight
corrected for gestational age, enrolment-
to-
delivery
3
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Figure 1 Sleep Apnea and Fetal Growth Restriction (SAFER) study flow chart. AHI, apnoea-hypopnoea index; BMI, body mass
index; FGR, fetal growth restriction; NICU, neonatal intensive care unit; OSA, obstructive sleep apnoea; PAP, positive airway
pressure; RCT, randomised controlled trial.
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Institution

Deliveries

US protocol used for
CS rate (%) estimated fetal weight

US fetal growth nomogram
used for FGR

Birthweight nomogram
used for SGA

University of Washington,
Barnes Jewish Hospital, St
Louis, Missouri

3576

31.4

Hadlock et al55

A US national reference for fetal Revised Fenton growth chart
growth.56
for preterm infants.57

University of Rochester,
Strong Hospital, Rochester,
New York

2859

34.9

Hadlock et al58

Local nomogram from 115 000
births in the nine-county Finger
Lakes Region, 2004–2013.59
60
(For Rochester birthweight
nomogram see online
supplemental file 2).

Local nomogram from
115 000 births in the
nine-county Finger Lakes
Region, 2004–2013.59 60
(For Rochester birthweight
nomogram see online
supplemental file 2).

Hadassah Hebrew University
Medical Center, Jerusalem,
Israel

8050
Ein Karem
campus

17.1

Hadlock et al58

International estimated fetal
weight standards of the
INTERGROWTH-21st Project.61

Birthweight standards in the
liveborn population in Israel.62

5812
Mt Scopus
campus

16.8

CS, caesarean section; FGR, fetal growth restriction; SAFER, Sleep Apnea and Fetal Growth Restriction; SGA, small for gestational age; US, ultrasound.

interval, gestational age at delivery and neonatal
outcomes.
All three stages of this international, multicentre study
will be conducted at three academic medical centres,
which all serve a large and diverse population of high-
risk obstetric patients. These centres are: Washington
University School of Medicine in St Louis, Missouri
(Barnes-Jewish Hospital); University of Rochester, New
York (Strong Memorial Hospital); and Hadassah Hebrew
University Medical Center, Jerusalem, Israel (Hadassah
Hospital, Ein Karem and Hadassah Hospital, Mt Scopus).
The demographic characteristics of these hospitals are
summarised in table 1.
There is lack of clarity in current guidelines over the
use of the term FGR. We use the American College of
Obstetrics and Gynecology definition of FGR as estimated
fetal weight below the 10th percentile for a population,5
and small for gestational age (SGA) as birth weight below
the 10th percentile.
Patient and public involvement
In an unpublished pilot study completed prior to completion of this protocol, pregnant volunteers used HSAT as
described in stage 2, and OSA-positive subjects used PAP
as described in stage 3. The pilot study allowed investigators to assess the night-time tolerability of both HSAT
and PAP for participants. Out of 57 patients who received
HSAT, 52 had data adequate for analysis. Of these 52
patients, 10 met OSA criteria for PAP use (see below);
however, one had an urgent delivery before PAP could be
distributed. Of the remaining nine subjects, one declined
to use PAP, one could not tolerate it and all the remaining
seven met PAP adherence criteria (see below). Generally,
adherence and comfort were good for both HSAT and
PAP.
As part of the effort to design the study with a tolerable intervention and a meaningful outcome, two of our
principal investigators met with community obstetricians,
4

primary care physicians and with a non-profit organisation advocating for high-risk pregnant maternal health,
in order to discuss the study and obtain feedback well in
advance of its final iteration.
Study participants
Inclusion criteria
This study enrols participants in a three-stage protocol.
We enrol pregnant women, aged 18–50 years, who have
been diagnosed with established FGR. FGR is defined as
estimated fetal weight <10th percentile based on at least
one routine second trimester ultrasound without a subsequent increase to >15th percentile on any ultrasounds
prior to enrolment. If the ultrasound that identified FGR
was performed prior to 21 completed weeks, a repeat
scan after 22 weeks is required to confirm the diagnosis
of FGR prior to enrolment. The lower limit of gestational
age at enrolment to stage 1 is 22+0 weeks; the upper limit
of gestational age at enrolment to stage 1 is an adequate
gestational age to be able to complete stages 1 and 2 and,
if appropriate, to receive stage 3 intervention by no later
than 32+0 weeks.
Exclusion criteria
The following exclusion criteria apply at the time of
enrolment: prespecified independent cause of FGR
(congenital or genetic anomalies, suspected aneuploidy
with two minor or one major markers, intrauterine infection or multiple gestation); active labour; a concrete decision already made to induce labour or perform caesarean
delivery within 2 days; reverse end-diastolic flow in the
umbilical artery (note that other abnormal Doppler flow
velocities such as absent end-diastolic flow in the umbilical
artery or uterine artery notching or increased pulsatility
index are not exclusion criteria unless other exclusion
criteria are present); pre-
existing formal diagnosis of
OSA; chronic pulmonary disease; haemoglobinopathies
(including thalassemia major and sickle cell disease, but
Hincker A, et al. BMJ Open 2021;11:e049120. doi:10.1136/bmjopen-2021-049120
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Table 1 Demographic characteristics of the medical centres in the SAFER study (data for 2019)
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Stage 1: initial screening for OSA risk
Stage 1 of the trial is designed in accordance with the
Strengthening the Reporting of Observational Studies
in Epidemiology (STROBE) statement (https://www.
strobe-statement.org). Potential participants with FGR as
defined above are identified through referral from the
obstetric ultrasound service, directly from the obstetrician
or by review of the electronic medical record. Those who
meet inclusion and exclusion criteria are approached for
consent either by telephone, in the outpatient clinics or
as inpatients by a member of the research team. Participants undergo a brief screening questionnaire to assess
for risk of OSA. Participants are deemed to be at risk for
OSA if they report loud snoring, report witnessed gasping
for air during sleep, have an Epworth score >10 or a Facco
score >75 (see figure 1).20 Participants with evidence of
OSA risk are invited to proceed to stage 2.
Stage 2: HSAT and OSA screening tools
Participants identified as being at risk for OSA in stage
1 progress to stage 2. The primary assessment for
confirming OSA diagnosis in this study is HSAT. Stage 2
of the trial is an observational study designed in accordance with the STROBE statement (https://www.strobe-
statement.org/).
Prior to HSAT, participants are assessed for demographic data, medical comorbidities, body mass index,
neck circumference and the presence of any craniofacial
abnormalities. They also undergo a more detailed OSA
assessment consisting of component parts of five standard
OSA screening tools (STOP-
BANG, Berlin Questionnaire, American Society of Anesthesiologists checklist,
Flemons Index and Epworth Sleepiness Scale). These
screening tools for OSA have each been validated in the
non-pregnant population; some but not all have been
validated in pregnancy.20 38 39
HSAT is performed with a Food and Drug
Administration-
approved type III home sleep monitor
(ResMed Apnea Link Air, ResMed, San Diego, California), which records the following: (1) air flow using
nasal cannula and pressure transducer; (2) respiratory
effort using elastic respiratory inductance plethysmography belts around the chest and abdomen; (3) ECG;
and (4) pulse oximetry.40 A trained member of the study
team shows each study participant how to apply the
sensors and use the HSAT monitor and instructs her to
wear the HSAT monitor for two consecutive nights. The
Hincker A, et al. BMJ Open 2021;11:e049120. doi:10.1136/bmjopen-2021-049120

HSAT monitor data are downloaded, and studies are
reviewed and scored by a registered polysomnographic
technologist per standard scoring protocols for apnoea-
hypopnoea index (AHI) and oxygen desaturation index
(ODI).41 AHI is defined as the number of apnoeas plus
hypopnoeas on average each hour.
Hypopnoea is defined by the American Academy of
Sleep Medicine recommended rule 1A; where a hypopnoea requires all of the following to be met: (1) the peak
signal for respiratory excursions drops by ≥30% from
pre-event baseline; (2) the duration of the ≥30% drop is
≥10 s; and (3) there is a ≥3% oxygen desaturation from
pre-event baseline and/or the event is associated with an
arousal.41 ODI is defined as the number of ≥3% oxygen
desaturations per hour of sleep without the required
drop in peak signal excursions.
HSAT generally underestimates AHI compared with
PSG, as the entire study duration is used as the denominator when calculating AHI. These errors are most
evident in mild OSA.42 To maximise sensitivity to detect
OSA yet improve specificity in this pragmatic study, we
add an ODI ≥5 criterion in cases where AHI is between 5
and 10. Accordingly, an HSAT that is positive for OSA is
defined as either an AHI ≥5 with an ODI ≥5 or as an AHI
≥10 regardless of the ODI.
The second night of HSAT monitoring serves only as a
backup in case the first night is inadequate to determine
the AHI and ODI. Variables derived from HSAT include
AHI, ODI, SaO2 nadir and time with SaO2 <90%. Investigators, treating physicians and participants are blinded
to these results until after delivery. The only result that is
unblinded prior to delivery is the binary ‘OSA positive’
versus ‘OSA negative’ HSAT result. Participants with an
HSAT that is positive for OSA will proceed to stage 3. All
participants from stage 2 are followed through the time
of delivery and assessed for maternal and fetal outcomes
after delivery (details below).
Stage 3: randomised trial of PAP therapy
Participants diagnosed with OSA in stage 2 proceed to
stage 3, which is a randomised controlled trial (RCT) of
PAP versus standard care control. The RCT is designed in
accordance with the Consolidated Standards of Reporting
Trials statement (http://www.consort-statement.org).
The primary outcome is unadjusted birth weight.
Participants randomised to PAP are asked to use PAP
whenever sleeping, from the time of randomisation
until delivery. The PAP device is the ResMed AirSense
10 ‘AutoSet for Her’, set at the widest pressure range
of 4–20 cmH2O. The low end of the range is increased
if the participant indicates discomfort from a sensation
of insufficient air pressure. During set-up, participants
select from full face mask, nasal mask or nasal pillow
interfaces, depending on comfort and fit. Initial set-up
is performed by a team member with clinical experience
with PAP treatment. Participants can change their mask
interfaces ad libitum. Adherence to PAP is continuously
assessed remotely using a cloud-based monitoring system,
5
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not sickle trait or thalassemia minor without clinical manifestations); maternal craniofacial anomalies which might
impair the ability of the participant to use PAP appliances;
lack of proficiency in English (Rochester or St Louis) or
either Hebrew, Arabic or English (Jerusalem); inability to
understand the consent; and unwillingness or inability to
participate adequately in OSA screening (stage 1) or in
HSAT (stage 2). Note that poor adherence to PAP (stage
3) is not an exclusion criterion. PAP usage is recorded but
outcomes are assessed by intention to treat.
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Recruitment, randomisation and blinding
Participant recruitment occurs simultaneously at all
sites (Barnes-Jewish Hospital, Washington University in
St Louis; Strong Memorial Hospital, University of Rochester; and Hadassah Hebrew University Medical Center,
Jerusalem, Israel). Randomised allocation in stage 3
occurs only after participant enrolment to avoid selection bias. Randomised allocation is performed centrally
by random number generator using block randomisation
with 1:1 allocation to PAP versus non-PAP control, using
randomised blocks of either two or four participants.
Randomisation is stratified by study site; within each site,
blocks are trichotomised by AHI into low (AHI 5–15),
medium (AHI 16–30) or high (AHI >30) as defined
above. Only the coordinating-centre study coordinator
is unblinded to absolute AHI or AHI category. All sites
produce a weekly report on the number of eligible participants, the number of participants approached and the
number recruited. To aid data homogeneity, a central
data entry system is used (Research Electronic Data
Capture; REDCap). At each centre, the investigators have
a secure password allowing access to the protected database. After randomised allocation, the participant is notified of her allocation by the site investigator; subjects in
the PAP group are then instructed on PAP use and a mask
fitting session is scheduled. Participants are instructed
not to reveal their group allocation to the technicians
performing follow-up ultrasounds or to the obstetricians
making clinical management decisions.
Outcome measures and analysis
Primary outcome
The goal for stage 1 is to identify OSA risk as defined
above for the purpose of recruiting participants into
stage 2. The goal for stage 2 is to identify OSA based
on HSAT criteria as defined above for the purpose of
recruiting participants into stage 3. The goal for stage
3, and the primary outcome of the SAFER study, is the
impact of the randomised treatment intervention (PAP vs
standard care control) on unadjusted birth weight. Birth
weight is an endpoint driven by multiple factors including
intrauterine fetal growth velocity and gestational age
at delivery. These factors may not be independent of
each other, as frequently women with severe FGR have
6

interventional delivery performed remote from term,
either for fetal indications or for maternal indications
(typically when FGR is accompanied by pre-eclampsia).
The primary endpoint, unadjusted birth weight, will be
corrected for gestational age and by appropriate racial
and local nomograms in multivariate analysis.
Secondary outcomes
The secondary outcome of stage 1 is the percentage
of patients with FGR who screen positive for OSA. The
secondary outcome for stage 2 is the percentage of patients
who test positive for OSA in HSAT. These outcomes will
help determine the clinical feasibility and cost-effectiveness
of this strategy in the general population. An additional
secondary outcome of stage 2 is to assess the predictive
value of each of the OSA screening tools for identifying
OSA in pregnancy. Secondary outcomes of stage 3 are as
follows: (1) obstetric outcomes: ultrasound fetal growth
velocity,44 enrolment-to-delivery interval, gestational age
at delivery, birth weight (as a Z-score) corrected for gestational age45 using an algorithm to standardise gestational
age,46 stillbirth; (2) neonatal outcomes: Apgar score, rate
of admission to higher levels of care (NICU or special
care nursery), length of neonatal stay.
Exploratory outcomes of stage 3 are as follows: (1)
obstetric outcomes: mode of delivery, umbilical cord gases,
umbilical artery blood flows; (2) maternal outcomes:
postpartum depression Edinburgh Postnatal Depression Scale (EPDS) score, rate of hypertensive disorders
of pregnancy, rate of gestational diabetes mellitus; (3)
neonatal outcomes: postnatal hypoglycaemia (<40 mg/
dL at any time)47 and/or requirement for intravenous
glucose treatment based on American Academy of Pediatrics guidelines,48 rates of hypoxic ischaemic neonatal
encephalopathy, neonatal death in first year of life.
Primary and secondary outcomes are compared
between the two study groups in stage 3 (OSA-positive
patients randomised to standard care with no PAP vs
those randomised to PAP therapy). We use intention-to-
treat analysis.
Planned subgroup analyses
We plan the following subgroup analyses:
PAP use
The effect of PAP on primary and secondary outcomes
based not on intention to treat, but rather on PAP adherence (as described above). The clinical justification of
this subgroup allocation is to assess whether a negative
or a borderline primary outcome of SAFER may mask a
true clinical effect of PAP when used with good adherence. This subgroup analysis will also accommodate the
unlikely crossover of a patient allocated to the no-PAP
control in stage 3, but who is subsequently referred by
their primary physician or obstetrician for OSA work-up
(not current standard of care) and who goes on to receive
PAP.
Hincker A, et al. BMJ Open 2021;11:e049120. doi:10.1136/bmjopen-2021-049120
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Airview (ResMed). In case of malfunction of this system,
adherence is also recorded by a memory card in each PAP
device. Adherence is monitored twice in the first week,
then weekly until the end of the study. We have defined
acceptable adherence to PAP as ≥4 hours of treatment on
≥70% of nights from the first night after PAP set-up to
the night prior to delivery. This definition is based on the
Centers for Medicare and Medicaid Services guideline.43
If a participant does not meet this benchmark based on
the nights studied, she receives a call from a team member
and is offered a troubleshooting visit to reassess mask fit,
machine settings and other changes in equipment in
order to try to improve adherence.
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Planned exploratory subgroup analyses
PAP use
The effect of PAP usage as a continuous variable (mean
hours of PAP use per night) on primary and secondary
outcomes; the purpose of this exploratory subgroup analysis is to explore the possible dose-response effect of PAP.
OSA severity
The effect of PAP on primary and secondary outcomes
with stratification by secondary measures from the HSAT:
ODI, SpO2 nadir and time with SpO2 <90%; where the
stratification into mild, moderate and severe will be
determined after examining the distribution of data;
the purpose of this exploratory subgroup analysis is to
explore whether other measures of OSA severity, particularly oxygen desaturation, are useful to direct which
patients may benefit from PAP therapy.
Effect of untreated OSA
Comparison between OSA-negative patients from stage 2
versus untreated OSA-positive patients (non-PAP control)
from stage 3 (we anticipate this will be approximately a
3:1 ratio); the purpose of this exploratory subgroup analysis is to assess the deleterious effects of OSA on maternal
and fetal outcomes in these patients.
Statistical analysis
Data are assessed for normality by visual inspection of
the frequency plot (histogram) and Q-Q plot of each
outcome variable and by the Kolmogorov-Smirnov test.
Normally distributed data are presented as mean (SD);
non-normally distributed data are presented as median
(IQR). Our primary outcome (birth weight) (derived from
stage 3) is assessed by two-tailed parametric t-test (normal
distribution) or non-parametric Wilcoxon rank-sum test
(non-normal distribution) as appropriate, using intention to treat as the grouping variable. The same tests
are used for other continuous secondary outcome variables (gestational age at delivery; enrolment-to-delivery
interval; birth weight corrected for gestational age;
Apgar and umbilical cord gas). For categorical outcomes
(higher level nursery admission; stillbirth; compliance
with PAP), the χ2 test or Fisher’s exact test (if expected
cells are small) is used as appropriate. Additionally, we
Hincker A, et al. BMJ Open 2021;11:e049120. doi:10.1136/bmjopen-2021-049120

use a mixed effects regression model to assess the effect
of PAP on the longitudinal association between estimated
fetal weight and Doppler ultrasound umbilical artery
flow, while controlling for maternal, obstetric and fetal
variables that may affect the primary outcome. Only the
intercept will be specified as the random component to
account for any omitted variable. By standard convention, statistical significance is based on a two-sided p value
<0.05 to determine the significance of association. Statistical testing is currently planned to use SAS V.9.4 (SAS
Institute).
Sample size calculation
The baseline birth weight of infants with FGR in the
population from our primary study centre (Barnes-Jewish
Hospital, St Louis, Missouri) is 2535±234 g (unpublished
data). Based on these data, we calculated that 104 evaluable participants with OSA will need to be randomised
to either PAP or control (stage 3) in order to have 90%
power to detect a 150 g difference in birth weight in the
PAP group compared with control. This is based on an
alpha of 0.05, anticipated 5% loss to follow-up and a two-
tailed t-test.
The risk of OSA in high-risk obstetric populations (such
as FGR) is as high as 35%.49 As we are screening participants for OSA risk by a brief telephone or in-person
questionnaire (stage 1) prior to HSAT testing (stage 2),
we estimate that there will be an OSA-positive HSAT in
30%–50% of these screened participants. Consequently,
we estimate that we will need to assess HSAT in 200–350
participants in stage 2 in order to achieve our sample
size of 104 evaluable participants for stage 3. We estimate
needing to screen some 500–1000 participants in stage 1
in order to identify these 200–350 participants for stage
2. Based on an estimated combined total of 20 000 births
annually with an estimated incidence of 15% of FGR at
the above centres, we estimate 3000 pregnancies complicated by FGR each year. Accounting for participants who
will not meet study inclusion criteria, or will decline to
participate, the recruitment process is expected to last
approximately 2 years.
Analysis of pragmatic elements of the SAFER study
The SAFER study is a pragmatic trial. The pragmatic
elements of the study were quantified using the Pragmatic Explanatory Continuum Indicator Summary-2 tool
(https://www.precis-2.org). Data were obtained from the
principal investigators in all study centres. According
to six of the nine criteria, the SAFER study is largely a
pragmatic study (figure 2). The study is particularly pragmatic for experimental intervention (a standard commercially available product), follow-up, relevance of clinical
outcomes and analysis. It is more explanatory for patient
selection/recruitment and organisational intervention.
This is because OSA work-up is not currently a standard
of care for FGR and patients only reach stage 3 if they
have FGR with HSAT-verified OSA. In this way, the study
targets patients most likely to experience benefits in fetal
7

BMJ Open: first published as 10.1136/bmjopen-2021-049120 on 29 June 2021. Downloaded from http://bmjopen.bmj.com/ on August 19, 2021 by guest. Protected by copyright.

OSA severity
The effect of PAP on primary and secondary outcomes
with stratification by OSA severity (mild, AHI 5–15;
moderate, AHI 15–30; severe >30). We hypothesise that
maternal and fetal outcomes will be most improved
following PAP therapy in patients with the most severe
cases of OSA. The clinical justification of this subgroup
allocation is to assess whether a negative or borderline
primary outcome of SAFER may mask a true clinical effect
of PAP when used in patients with more severe OSA; this
may also aid in the determination of an optimal target
population based on OSA severity for clinical use of PAP
in FGR.
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growth from PAP, but the generalisability to other populations may be more limited.
Strengths and limitations
The SAFER study has important strengths. It is a multicentre study of a safe, routinely available intervention that
examines an easily measured outcome with important
short-term and long-term ramifications for the well-being
of neonates and possibly for later adult life. SAFER is a
pragmatic study and the intervention does not preclude
any existing approaches for the management of these
high-risk pregnancies. As PAP is worn only when sleeping,
typically at home, it is relatively easy to keep the research
team and clinical providers blinded to group allocation.
As the PAP device used in this study records PAP compliance, we do not have to rely on compliance self-reporting
which may overestimate nightly device use.
The SAFER study has several limitations. There is
currently no definitive estimate for the impact of PAP
on birth weight; hence, the effect measure used in the
sample size estimation may be inaccurate, which may
affect the study’s power in regard to our primary and
secondary endpoints. It is likely that follow-up studies will
be warranted, especially regarding whether or not the
results from this specific target population can be generalised to other pregnant women with FGR, or pregnant
women with OSA who may have pregnancy complications
without FGR, for example, pre-eclampsia. It is the intention of the investigators to follow-up a positive result (that
PAP increases intrauterine fetal growth) with a larger
study to assess long-term neonatal neurological outcome.
Estimates of fetal weight were all based on the Hadlock
formula using the standard biometric parameters
8

(biparietal diameter, head circumference, abdominal
circumference, femur length) [52, 53].50 51 However,
when converting fetal weight to a calculated percentile,
this must reference a ‘population or customized standard’.52 As this is a pragmatic multicentre study, each
study centre defines FGR and SGA by the population
or customised standard used in their routine care (see
table 1). This will lead to a slight difference between
centres in FGR and SGA definition. However, fetal growth
varies between different ethnic and geographical populations, so a single absolute imposed standard is of limited
relevance clinically. The impact of this factor in stage 3
is reduced by stratification of randomised allocation by
study centre.
Although investigators, treating physicians and ultrasound technicians are blinded to participant group allocation in this study, we do not blind participants. We
are confident that our primary outcome and all of the
secondary outcome measures (with the exception of the
EPDS) can be assessed blindly, which minimises the risk of
bias. We considered using sham PAP as a placebo control.
While this could minimise bias in evaluating the effect
of PAP, wearing an ineffective mask does increase the
risk of discomfort and sleep disturbances for the control
group, which potentially biases the results toward the
active group. A recent study53 demonstrated that there
was no difference in outcome between sham PAP and a
device-free control; however, most subjects in the sham
PAP group guessed correctly that they were receiving the
placebo intervention.
Home sleep testing may underestimate the true presence of SDB for several reasons, most notably because it
Hincker A, et al. BMJ Open 2021;11:e049120. doi:10.1136/bmjopen-2021-049120
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Figure 2 Pragmatic Explanatory Continuum Indicator Summary-2 (PRECIS-2) wheel for characterising the degree to which
elements of a study are more explanatory (toward the centre of the wheel) or pragmatic (toward the periphery).
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Potential benefits, risks and alternatives
Benefits
All participants reaching stage 2 of the study will potentially benefit from being identified as at risk for OSA and
being referred to their primary care physician for evaluation by a sleep physician after delivery.
Risks
The likelihood of adverse events in this study is low as
the devices that will be used in the study (HSAT and
aPAP) are ones that have been used in the general and
obstetric population for years. In the unlikely event that
serious side effects occur, these will be documented and
reported to the human research protection office and to
the study’s Data Safety Monitor.
Minimisation of risks to confidentiality
All participants are assigned a unique study ID number.
The link to identifiers will be destroyed at the end of the
study. Data will be stored under lock and key (office, file
cabinet) and only the investigators and research team will
Hincker A, et al. BMJ Open 2021;11:e049120. doi:10.1136/bmjopen-2021-049120

have access. If data are published, there will be no link to
identifiers. Study data are not entered into participants’
medical records. Data regarding PAP compliance are
downloaded from ResMed’s secure, cloud-based patient
management system to a secure server at the primary site
(Washington University), where they are stored for the
duration of the study.
Data from this study will be recorded using REDCap,
a web-based, Health Insurance Portability and Accountability Act-
compliant application. Access to the data
is password protected. REDCap servers are housed in
a secure data centre and information transmission is
encrypted.
Adverse event reporting and safety monitoring
The research team continuously monitors the study
for adverse events. All serious adverse events (SAEs)
are reported to the Institutional Review Board (IRB)
according to IRB stipulations. Additionally, an attending
anaesthesiologist at Washington University who is not
involved in the study serves as the Data Safety Monitor;
given the small size and relatively low-risk nature of the
protocol, an individual physician rather than a full Data
Safety Monitoring Board is used. This monitor reviews all
adverse events annually and reviews SAEs or unexpected
adverse events as they occur.
Premature study termination
The only interim analysis to be performed in this study
will be a single, blinded analysis performed by the Data
Safety Monitor at the mid-way point, after 52 patients
have completed stage 3. This interim analysis will assess
differences between groups in birth weight, gestational
age at delivery, intrauterine fetal death or reported major
adverse events. The study code will not be broken, and
other secondary endpoints will not be assessed. If there is
a statistically significant difference between groups in one
of these selected outcomes, then the Data Safety Monitor
will break the code. If the intervention is associated with
smaller birth weight, lower gestational age at delivery,
more intrauterine fetal death or more reported major
adverse events, then this will be brought to the attention
of the investigators and the primary study site IRB, for
consideration of possible premature termination of the
study on the grounds of increased harm due to the intervention. There will be no premature termination of the
study due to increased benefit of the intervention. Unless
there is an increased harm of the intervention, the Data
Safety Monitor will not give any information to the investigators regarding the interim analysis.
Ethics and dissemination
Informed consent for stage 1 may be by telephone, electronic or written consent. Informed consent for stages 2
and 3 is obtained by a study investigator using electronic
or written consent (see online supplemental file 1). There
are no additional risks associated with the screening study
(stage 1) or the observational HSAT study (stage 2). There
9
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uses the study duration as the denominator to calculate
AHI. In addition, in this study, our protocol may be over-
reliant on oxygen desaturation, as that feature may not be
as prominent in a young female pregnant population.50
Hence, our methods may underestimate the true prevalence and severity of SDB, and preferentially select the
study population with more severe SDB. This selected
population with more severe SDB may have a greater likelihood of exhibiting a clinical effect with PAP treatment.
However, in this pragmatic study, we need to use HSAT
so that the intervention can be started within as narrow a
time frame as possible.
This study uses intention-to-treat analysis to assess the
efficacy of the intervention. The adherence to PAP is relatively low across all populations.51 54 Adherence is generally higher for aPAP devices, as used in this study, when
compared with CPAP devices.51 Two recent large national
database studies reported conflicting results regarding
gender effects on PAP adherence—either lower in men51
or lower in women,54 although it is not known whether
any of these women were pregnant in those studies. It is
possible that pregnant women concerned about potentially optimising fetal and maternal outcomes would
be more adherent to PAP. We performed a pilot study
in preparation for this protocol (see the Patient and
public involvement section) in which we observed PAP
adherence in seven out of nine subjects tested. Our
calculated power does not specifically accommodate
non-adherence. Accordingly, we also describe a planned
subgroup analysis in which PAP adherence is used rather
than intention to treat. Ultimately, this pragmatic study
can only assess whether administering a PAP device will
improve outcomes in pregnancy. If PAP is not effective
during pregnancy because women do not adhere to it,
that raises a separate question that will require addressing
separately.
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INFORMED CONSENT DOCUMENT
Project Title:

Sleep Apnea and Fetal Growth Restriction

Principal Investigator:

Ellen Lockhart, MD

Research Team Contact:

Liz Wilson 314-454-5967

This consent form describes the research study and helps you decide if you want to participate. It
provides important information about what you will be asked to do during the study, about the risks and
benefits of the study, and about your rights and responsibilities as a research participant. By signing this
form you are agreeing to participate in this study.
• You should read and understand the information in this document including the procedures,
risks and potential benefits.
• If you have questions about anything in this form, you should ask the research team for more
information before you agree to participate.
• You may also wish to talk to your family or friends about your participation in this study.
• Do not agree to participate in this study unless the research team has answered your
questions and you decide that you want to be part of this study.

WHAT IS THE PURPOSE OF THIS STUDY?
This is a research study. We invite you to participate in this research study because you are
approximately 22-31 weeks pregnant and have been diagnosed with FGR fetal growth restriction.
The purpose of this research study is to help us understand if autotitrated positive airway pressure
(aPAP) can improve fetal growth in pregnant woman diagnosed with sleep apnea. aPAP is a machine
that gently delivers pressurized air, via a mask, to keep your airways free of obstruction as you sleep.
The air pressure delivered from the machines acts as a splint, keeping your throat open so that you can
breathe freely through the night.
The aPAP machine is approved by the U.S. Food and Drug Administration for the treatment of patients
with obstructive sleep apnea (OSA), central and/or mixed apneas or periodic breathing.
The home sleep monitoring device is approved by the U.S. Food and Drug Administration to aid in the
diagnosis of sleep disordered breathing in adult patients.
WHAT WILL HAPPEN DURING THIS STUDY?
If you decide to participate in this study, you will complete a sleep questionnaire either electronically or
on paper. You may refuse to answer any question on the questionnaire that makes you uncomfortable,
but it is pssible that you might not be able to participate in the study, depending on which question it is.
You will be provided with a home sleep monitoring device and instructed on how to use it. A home
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sleep monitor is a device that monitors your breathing while you sleep and determines whether or not
you have sleep apnea. You will wear the sleep monitor for two consecutive nights and fill out a short
sleep survey rating the quality of your sleep.
If the results of your home sleep test meet the study criteria, you will be eligible to advance to the final
stage of the study, where you will be randomized to either receive an aPAP (auto-titrating positive
airway pressure) device or no device.
If you are randomized to receive an aPAP device and mask, you will be expected to wear the device
each night when you sleep for the duration of your pregnancy. The aPAP device will provide data to the
study team to monitor compliance by indicating the number of hours each night that you wear the
device. We will collect the data daily from the device electronically via an internal modem. The data
transfers automatically and you do not have to do anything to make this happen. A member of the study
team will remain in contact with you throughout the study to provide support and answer any questions
or concerns you may have.
You will be provided with both paper instructions and educational videos for using the devices.
We will collect demographic data including name, date of birth, home address, phone number and email
address, and clinical data such as your height, weight, medical history, expected due date, obstetric
outcomes and fetal outcomes from your and your baby’s medical record.
We are looking for any connections between sleep apnea and low blood flow to your baby. It is routine
practice for doctors of patients with fetal growth restriction to send the placenta to pathology for
analysis. If you agree, we may take a small slice for our research study.
Please place your initials in the blank next to Yes or No for each of the questions below:
You may use a small slice of my placenta tissue to look for genes that might help us to understand
markers of low blood flow to the placenta
_____ Yes

_____ No

Initials

Initials

After your baby is born, we would like to review their medical chart relating to their 18 – 24 month visit
for the results of a routine test the pediatrician may do called the “Bayley Score.” The Bayley Score is
an assessment of your child’s cognition, language and motor function.
Please place your initials in the blank next to Yes or No for each of the questions below:
You may check my child’s electronic medical record for their 18-24-month follow-up visit to
access the Bayley Score.
_____ Yes

_____ No

Initials

Initials
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After the study is complete, if the results of your home sleep test meet criteria you will be referred to
your OB or PCP for a possible referral to a sleep physician.

Will you save my research information and/or biospecimens to use in future research studies?
We would like to use the data and tissue we are obtaining in this study for studies going on right now as
well as studies that are conducted in the future. These studies may provide additional information that
will be helpful in understanding fetal growth restriction, or other diseases or conditions, including
research to develop investigational tests, treatments, drugs or devices that are not yet approved by the
U.S. Food and Drug Administration. It is unlikely that what we learn from these studies will have a
direct benefit to you. There are no plans to provide financial compensation to you should this occur. By
allowing us to use your data and tissue you give up any property rights you may have in the data and
tissue.
We might remove identifiers from your private information and your data and tissue and then use the
information and your data and tissue for future research studies or share them with other researchers for
their future research. This future research may involve studying genes from your tissue samples. If this
occurs we will not ask you for additional consent for these uses of your information or data and tissue.
We will share your data and tissue with other researchers. They may be doing research in areas similar
to this research or in other unrelated areas. These researchers may be at Washington University, at other
research centers and institutions, or industry sponsors of research. We may also share your research data
with large data repositories (a repository is a database of information) for broad sharing with the
research community. If your individual research data is placed in one of these repositories only
qualified researchers, who have received prior approval from individuals that monitor the use of the
data, will be able to look at your information.
Your data and tissue will be stored without your name or any other kind of link that would enable us to
identify which sample(s) or data are yours. Therefore, it will be available for use in future research
studies indefinitely and cannot be removed.
HOW MANY PEOPLE WILL PARTICIPATE?
Approximately 34 people will take part in this study conducted by investigators at Washington
University. Approximately 104 people will take part in the study worldwide.
HOW LONG WILL I BE IN THIS STUDY?
If you agree to take part in this study, your physical involvement will last for the duration of your
pregnancy, and long-term follow-up will conclude at 18-24 months with the collection of your baby’s
Bayley scores from EMR.
WHAT ARE THE RISKS OF THIS STUDY?
You may experience one or more of the risks indicated below from being in this study. In addition to
these, there may be other unknown risks, or risks that we did not anticipate, associated with being in this
02/05/2020
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study.
Home Sleep monitor: You may experience mild discomfort from the device and mild inconvenience.
APAP device: You may experience mild discomfort from the device and mild inconvenience. A
properly functioning aPAP device will sense subtle changes in your breathing and adjust itself to the
best pressure setting for you. If your machine is malfunctioning, you many not receive adequate
pressure. We will be able to see this and can provide you with another. Other risks include:
1. Irritation of facial skin from the PAP mask (common, mild). A mask fitting will be performed by a
registered sleep technologist, and if skin irritation occurs, you can return for further mask fittings.
2. Irritation and dryness of nasal passages (common, mild). Every PAP machine will be dispensed with
a humidifier and filters to minimize irritation and dryness to the nasal passages.
3. Sensation of fullness in chest (rare, mild): Some individuals feel like the pressurized air from the
PAP machine causes a sensation of fullness in the chest. This usually resolves spontaneously after
several days of usage.
4. Worse sleep quality due to mask on face, noise from machine, or unfamiliar sleeping environment
(common, mild). This usually resolves as a person gets accustomed to using PAP.
Genetic Research
There is a federal law called the Genetic Information Nondiscrimination Act (GINA). In general, this
law makes it illegal for health insurance companies, group health plans and employers with greater than
15 employees to discriminate against you based on your genetic information. However, it does not
protect you against discrimination by companies that sell life insurance, disability insurance or long
term-care insurance.
Breach of Confidentiality
One risk of participating in this study is that confidential information about you may be accidentally
disclosed. We will use our best efforts to keep the information about you secure. Please see the section
in this consent form titled “How will you keep my information confidential?” for more information.
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WHAT ARE THE BENEFITS OF THIS STUDY?
You may or may not benefit from being in this study.
However, we hope that, in the future, other people might benefit from this study because we will gain a
better understanding of treatment of obstructive sleep apnea during pregnancy.
WILL IT COST ME ANYTHING TO BE IN THIS STUDY?
You will not have any costs for being in this research study.
You and/or your medical/hospital insurance provider will remain responsible for your regular medical
care expenses.
WILL I BE PAID FOR PARTICIPATING?
You will be paid for being in this research study. You will need to provide your social security number
(SSN) in order for us to pay you. You may choose to participate without being paid if you do not wish to
provide your social security number (SSN) for this purpose. If your social security number is obtained
for payment purposes only, it will not be retained for research purposes.
You will receive a $25 Target gift card upon completion of the home sleep study and return of the
device. If you are eligible and randomized to wear an aPAP device, you will be given a $25 Target gift
card for compliance and at $25 Target gift card following return of the device after delivery. You could
receive up to $75 in Target gift cards if you complete the study and are compliant wearing the aPAP.
WHO IS FUNDING THIS STUDY?
The RESMED Foundation is funding this research study. This means that Washington University is
receiving payments from the RESMED Foundation to support the activities that are required to conduct
the study. No one on the research team will receive a direct payment or increase in salary from the
RESMED Foundation for conducting this study.
WHAT IF I AM INJURED AS A RESULT OF THIS STUDY?
Washington University investigators and staff will try to reduce, control, and treat any complications
from this research. If you feel you are injured because of the study, please contact the investigator Alex
Hincker at 314-362-2628 and/or the Human Research Protection Office at 1-(800)-438-0445.
Decisions about whether payment for medical treatment for injuries relating to your participation in
research will be made by Washington University. If you need to seek medical care for a research-related
injury, please notify the investigator as soon as possible.
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HOW WILL YOU KEEP MY INFORMATION CONFIDENTIAL?
Other people such as those indicated below may become aware of your participation in this study and
may inspect and copy records pertaining to this research. Some of these records could contain
information that personally identifies you. We will keep your participation in this research study
confidential to the extent permitted by law.
• Government representatives (including the Office for Human Research Protections) to complete
federal or state responsibilities
• The U.S. Food and Drug Administration
• The RESMED Foundation
• Your primary care physician if a medical condition that needs urgent attention is discovered
• Hospital or University representatives to complete Hospital or University responsibilities
• Information about your participation in this study may be documented in your health care records
and will be available to anyone with access to your health care record, including your health
insurance company. This information may also be released as part of a release of information
request.
• The last four digits of your social security number may be used in hospital or University systems
to track billing information for research procedures.
• Washington University’s Institutional Review Board (a committee that oversees the conduct of
research involving human participants) and the Human Research Protection Office. The
Institutional Review Board has reviewed and approved this study.
• Any report or article that we write will not include information that can directly identify you.
The journals that publish these reports or articles require that we share your information that was
collected for this study with others to make sure the results of this study are correct and help
develop new ideas for research. Your information will be shared in a way that cannot directly
identify you.
To help protect your confidentiality, we will have all paper documents locked in a filing cabinet in a
locked office of a member of the study team. We will keep all electronic documents on secured servers
that are password protected and have various state of the art firewall protections with frequent upgrades
of these protections. Access to these electronic research files will be restricted to members of the
research team and will be controlled by the principal investigator.
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required by U.S.
Law. This Web site will not include information that can identify you. At most, the Web site will
include a summary of the results. You can search this Web site at any time.
Are there additional protections for my health information?
Protected Health Information (PHI) is health information that identifies you. PHI is protected by federal
law under HIPAA (the Health Insurance Portability and Accountability Act). To take part in this
research, you must give the research team permission to use and disclose (share) your PHI for the study
as explained in this consent form. The research team will follow state and federal laws and may share
your health information with the agencies and people listed under the previous section titled, “How will
you keep my information confidential?”
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Once your health information is shared with someone outside of the research team, it may no longer be
protected by HIPAA.
The research team will only use and share your information as talked about in this form or as permitted or
required by law. When possible, the research team will make sure information cannot be linked to you
(de-identified). Once information is de-identified, it may be used and shared for other purposes not
discussed in this consent form. If you have questions or concerns about your privacy and the use of your
PHI, please contact the University’s Privacy Officer at 866-747-4975.
Although you will not be allowed to see the study information, you may be given access to your health
care records by contacting your health care provider.
If you decide not to sign this form, it will not affect
• your treatment or the care given by your health provider.
• your insurance payment or enrollment in any health plans.
• any benefits to which you are entitled.
However, it will not be possible for you to take part in the study.
If you sign this form:
• You authorize the use of your PHI for this research
• This authorization does not expire.
• You may later change your mind and not let the research team use or share your information
(you may revoke your authorization).
• To revoke your authorization, complete the withdrawal letter, found in the Participant section
of the Human Research Protection Office website at
https://hrpo.wustl.edu/participants/withdrawing-from-a-study/ or you may request that the
investigator send you a copy of the letter.
o If you revoke your authorization:
 The research team may only use and share information already collected for
the study.
 Your information may still be used and shared as necessary to maintain the
integrity of the research, for example, to account for a participant’s
withdrawal from the research study or for safety reasons.
 You will not be allowed to continue to participate in the study.

Can we contact you by email?
We would like to contact you by email for the purposes listed below. Some of these emails may contain
health information that identifies you.
•
•

Patient education
Appointment scheduling, which may contain PHI

Only the research team will have access to your email communications. We will only communicate by
email to send you the information listed above. If you have any questions or need to contact us for an
02/05/2020
Page 7 of 10

Hincker A, et al. BMJ Open 2021; 11:e049120. doi: 10.1136/bmjopen-2021-049120

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)

BMJ Open

urgent or emergent situation, please contact the research team member identified at the top of this
document.
You should be aware that there are risks associated with sending your health information via email.
• There is always a risk that the message could be intercepted or sent to the wrong email
address. To avoid sending messages to the wrong email address, the first email we send you
will be a test message to ensure we have the correct email address.
• When using any computer you should be careful to protect your username and password.
Make sure you log-out before getting up from the computer.
• If you share a home computer with other family members, and do not want them to know you
are participating in this study make sure you provide an email address that only you can
access.
• Your employer will have access to any email communications sent or received on any
electronic devices used for work or through a work server.
Do you agree to allow us to send your health information via email?
_____ Yes

_____ No

Initials

Initials

IS BEING IN THIS STUDY VOLUNTARY?
Taking part in this research study is completely voluntary. You may choose not to take part at all. If
you decide to be in this study, you may stop participating at any time. Any data that was collected as
part of your participation in the study will remain as part of the study records and cannot be removed.
If you decide not to be in this study, or if you stop participating at any time, you won’t be penalized or
lose any benefits for which you otherwise qualify.
What if I decide to withdraw from the study?
You may withdraw by telling the study team you are no longer interested in participating in the study or
you may send in a withdrawal letter. A sample withdrawal letter can be found at
https://hrpo.wustl.edu/participants/withdrawing-from-a-study/ under Withdrawing from a Research
Study.
If you decide to leave the study early, we will ask you to return the home sleep monitor and aPAP
machines.
If you withdraw from the study we will ask your permission to continue to collect information from your
health care records. Should this occur we will ask you to sign a separate consent form before collecting
this information.
Will I receive new information about the study while participating?
If we obtain any new information during this study that might affect your willingness to continue
participating in the study, we’ll promptly provide you with that information.
02/05/2020
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Can someone else end my participation in this study?
Under certain circumstances, the investigator might decide to end your participation in this research
study earlier than planned. This might happen for no reason or because in our judgment it would not be
safe for you to continue, because funding for the research study has ended, because the sponsor has
decided to stop the research.
WHAT IF I HAVE QUESTIONS?
We encourage you to ask questions. If you have any questions about the research study itself, please
contact: Liz Wilson 314-454-5967. If you experience a research-related injury, please contact: Alex
Hincker at 314-362-2628.
If you have questions, concerns, or complaints about your rights as a research participant, please contact
the Human Research Protection Office 1-(800)-438-0445, or email hrpo@wustl.edu. General
information about being a research participant can be found on the Human Research Protection Office
web site, http://hrpo.wustl.edu. To offer input about your experiences as a research participant or to
speak to someone other than the research staff, call the Human Research Protection Office at the number
above.
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This consent form is not a contract. It is a written explanation of what will happen during the study if
you decide to participate. You are not waiving any legal rights by agreeing to participate in this study.
As a participant you have rights and responsibilities as described in this document and including:
• To be given enough time before signing below to weigh the risks and potential benefits and
decide if you want to participate without any pressure from the research team or others.
• To understand all of the information included in the document, have your questions answered,
and receive an explanation of anything you do not understand.
• To follow the procedures described in this document and the instructions of the research team to
the best of your ability unless you choose to stop your participation in the research study.
• To give the research team accurate and complete information.
• To tell the research team promptly about any problems you have related to your participation, or
if you are unable to continue and wish to stop participating in the research study.
Your signature indicates that this research study has been explained to you, that your questions have
been answered, and that you agree to take part in this study. You will receive a signed and dated copy
of this form.

Do not sign this form if today’s date is after $STAMP_EXP_DT.
__________________________________________
(Signature of Participant)

_______________________________
(Date)

____________________________________________
(Participant's name – printed)

Statement of Person Who Obtained Consent
The information in this document has been discussed with the participant or, where appropriate, with the
participant’s legally authorized representative. The participant has indicated that they understand the
risks, benefits, and procedures involved with participation in this research study.

__________________________________________
(Signature of Person who Obtained Consent)

_______________________________
(Date)

___________________________________________
(Name of Person who Obtained Consent - printed)
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University of Rochester / Strong Hospital - Birth weight nomogram
Local nomogram from 115,000 births in the nine-county Finger Lakes Region, 2004-2013. [60, 61]
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INFORMED CONSENT DOCUMENT
Project Title:

Sleep Apnea and Fetal Growth Restriction

Principal Investigator:

Ellen Lockhart, MD

Research Team Contact:

Liz Wilson 314-454-5967

This consent form describes the research study and helps you decide if you want to participate. It
provides important information about what you will be asked to do during the study, about the risks and
benefits of the study, and about your rights and responsibilities as a research participant. By signing this
form you are agreeing to participate in this study.
• You should read and understand the information in this document including the procedures,
risks and potential benefits.
• If you have questions about anything in this form, you should ask the research team for more
information before you agree to participate.
• You may also wish to talk to your family or friends about your participation in this study.
• Do not agree to participate in this study unless the research team has answered your
questions and you decide that you want to be part of this study.

WHAT IS THE PURPOSE OF THIS STUDY?
This is a research study. We invite you to participate in this research study because you are
approximately 22-31 weeks pregnant and have been diagnosed with FGR fetal growth restriction.
The purpose of this research study is to help us understand if autotitrated positive airway pressure
(aPAP) can improve fetal growth in pregnant woman diagnosed with sleep apnea. aPAP is a machine
that gently delivers pressurized air, via a mask, to keep your airways free of obstruction as you sleep.
The air pressure delivered from the machines acts as a splint, keeping your throat open so that you can
breathe freely through the night.
The aPAP machine is approved by the U.S. Food and Drug Administration for the treatment of patients
with obstructive sleep apnea (OSA), central and/or mixed apneas or periodic breathing.
The home sleep monitoring device is approved by the U.S. Food and Drug Administration to aid in the
diagnosis of sleep disordered breathing in adult patients.
WHAT WILL HAPPEN DURING THIS STUDY?
If you decide to participate in this study, you will complete a sleep questionnaire either electronically or
on paper. You may refuse to answer any question on the questionnaire that makes you uncomfortable,
but it is pssible that you might not be able to participate in the study, depending on which question it is.
You will be provided with a home sleep monitoring device and instructed on how to use it. A home
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sleep monitor is a device that monitors your breathing while you sleep and determines whether or not
you have sleep apnea. You will wear the sleep monitor for two consecutive nights and fill out a short
sleep survey rating the quality of your sleep.
If the results of your home sleep test meet the study criteria, you will be eligible to advance to the final
stage of the study, where you will be randomized to either receive an aPAP (auto-titrating positive
airway pressure) device or no device.
If you are randomized to receive an aPAP device and mask, you will be expected to wear the device
each night when you sleep for the duration of your pregnancy. The aPAP device will provide data to the
study team to monitor compliance by indicating the number of hours each night that you wear the
device. We will collect the data daily from the device electronically via an internal modem. The data
transfers automatically and you do not have to do anything to make this happen. A member of the study
team will remain in contact with you throughout the study to provide support and answer any questions
or concerns you may have.
You will be provided with both paper instructions and educational videos for using the devices.
We will collect demographic data including name, date of birth, home address, phone number and email
address, and clinical data such as your height, weight, medical history, expected due date, obstetric
outcomes and fetal outcomes from your and your baby’s medical record.
We are looking for any connections between sleep apnea and low blood flow to your baby. It is routine
practice for doctors of patients with fetal growth restriction to send the placenta to pathology for
analysis. If you agree, we may take a small slice for our research study.
Please place your initials in the blank next to Yes or No for each of the questions below:
You may use a small slice of my placenta tissue to look for genes that might help us to understand
markers of low blood flow to the placenta
_____ Yes

_____ No

Initials

Initials

After your baby is born, we would like to review their medical chart relating to their 18 – 24 month visit
for the results of a routine test the pediatrician may do called the “Bayley Score.” The Bayley Score is
an assessment of your child’s cognition, language and motor function.
Please place your initials in the blank next to Yes or No for each of the questions below:
You may check my child’s electronic medical record for their 18-24-month follow-up visit to
access the Bayley Score.
_____ Yes

_____ No

Initials

Initials

02/05/2020
Page 2 of 10

Hincker A, et al. BMJ Open 2021; 11:e049120. doi: 10.1136/bmjopen-2021-049120

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)

BMJ Open

After the study is complete, if the results of your home sleep test meet criteria you will be referred to
your OB or PCP for a possible referral to a sleep physician.

Will you save my research information and/or biospecimens to use in future research studies?
We would like to use the data and tissue we are obtaining in this study for studies going on right now as
well as studies that are conducted in the future. These studies may provide additional information that
will be helpful in understanding fetal growth restriction, or other diseases or conditions, including
research to develop investigational tests, treatments, drugs or devices that are not yet approved by the
U.S. Food and Drug Administration. It is unlikely that what we learn from these studies will have a
direct benefit to you. There are no plans to provide financial compensation to you should this occur. By
allowing us to use your data and tissue you give up any property rights you may have in the data and
tissue.
We might remove identifiers from your private information and your data and tissue and then use the
information and your data and tissue for future research studies or share them with other researchers for
their future research. This future research may involve studying genes from your tissue samples. If this
occurs we will not ask you for additional consent for these uses of your information or data and tissue.
We will share your data and tissue with other researchers. They may be doing research in areas similar
to this research or in other unrelated areas. These researchers may be at Washington University, at other
research centers and institutions, or industry sponsors of research. We may also share your research data
with large data repositories (a repository is a database of information) for broad sharing with the
research community. If your individual research data is placed in one of these repositories only
qualified researchers, who have received prior approval from individuals that monitor the use of the
data, will be able to look at your information.
Your data and tissue will be stored without your name or any other kind of link that would enable us to
identify which sample(s) or data are yours. Therefore, it will be available for use in future research
studies indefinitely and cannot be removed.
HOW MANY PEOPLE WILL PARTICIPATE?
Approximately 34 people will take part in this study conducted by investigators at Washington
University. Approximately 104 people will take part in the study worldwide.
HOW LONG WILL I BE IN THIS STUDY?
If you agree to take part in this study, your physical involvement will last for the duration of your
pregnancy, and long-term follow-up will conclude at 18-24 months with the collection of your baby’s
Bayley scores from EMR.
WHAT ARE THE RISKS OF THIS STUDY?
You may experience one or more of the risks indicated below from being in this study. In addition to
these, there may be other unknown risks, or risks that we did not anticipate, associated with being in this
02/05/2020
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study.
Home Sleep monitor: You may experience mild discomfort from the device and mild inconvenience.
APAP device: You may experience mild discomfort from the device and mild inconvenience. A
properly functioning aPAP device will sense subtle changes in your breathing and adjust itself to the
best pressure setting for you. If your machine is malfunctioning, you many not receive adequate
pressure. We will be able to see this and can provide you with another. Other risks include:
1. Irritation of facial skin from the PAP mask (common, mild). A mask fitting will be performed by a
registered sleep technologist, and if skin irritation occurs, you can return for further mask fittings.
2. Irritation and dryness of nasal passages (common, mild). Every PAP machine will be dispensed with
a humidifier and filters to minimize irritation and dryness to the nasal passages.
3. Sensation of fullness in chest (rare, mild): Some individuals feel like the pressurized air from the
PAP machine causes a sensation of fullness in the chest. This usually resolves spontaneously after
several days of usage.
4. Worse sleep quality due to mask on face, noise from machine, or unfamiliar sleeping environment
(common, mild). This usually resolves as a person gets accustomed to using PAP.
Genetic Research
There is a federal law called the Genetic Information Nondiscrimination Act (GINA). In general, this
law makes it illegal for health insurance companies, group health plans and employers with greater than
15 employees to discriminate against you based on your genetic information. However, it does not
protect you against discrimination by companies that sell life insurance, disability insurance or long
term-care insurance.
Breach of Confidentiality
One risk of participating in this study is that confidential information about you may be accidentally
disclosed. We will use our best efforts to keep the information about you secure. Please see the section
in this consent form titled “How will you keep my information confidential?” for more information.
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WHAT ARE THE BENEFITS OF THIS STUDY?
You may or may not benefit from being in this study.
However, we hope that, in the future, other people might benefit from this study because we will gain a
better understanding of treatment of obstructive sleep apnea during pregnancy.
WILL IT COST ME ANYTHING TO BE IN THIS STUDY?
You will not have any costs for being in this research study.
You and/or your medical/hospital insurance provider will remain responsible for your regular medical
care expenses.
WILL I BE PAID FOR PARTICIPATING?
You will be paid for being in this research study. You will need to provide your social security number
(SSN) in order for us to pay you. You may choose to participate without being paid if you do not wish to
provide your social security number (SSN) for this purpose. If your social security number is obtained
for payment purposes only, it will not be retained for research purposes.
You will receive a $25 Target gift card upon completion of the home sleep study and return of the
device. If you are eligible and randomized to wear an aPAP device, you will be given a $25 Target gift
card for compliance and at $25 Target gift card following return of the device after delivery. You could
receive up to $75 in Target gift cards if you complete the study and are compliant wearing the aPAP.
WHO IS FUNDING THIS STUDY?
The RESMED Foundation is funding this research study. This means that Washington University is
receiving payments from the RESMED Foundation to support the activities that are required to conduct
the study. No one on the research team will receive a direct payment or increase in salary from the
RESMED Foundation for conducting this study.
WHAT IF I AM INJURED AS A RESULT OF THIS STUDY?
Washington University investigators and staff will try to reduce, control, and treat any complications
from this research. If you feel you are injured because of the study, please contact the investigator Alex
Hincker at 314-362-2628 and/or the Human Research Protection Office at 1-(800)-438-0445.
Decisions about whether payment for medical treatment for injuries relating to your participation in
research will be made by Washington University. If you need to seek medical care for a research-related
injury, please notify the investigator as soon as possible.
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HOW WILL YOU KEEP MY INFORMATION CONFIDENTIAL?
Other people such as those indicated below may become aware of your participation in this study and
may inspect and copy records pertaining to this research. Some of these records could contain
information that personally identifies you. We will keep your participation in this research study
confidential to the extent permitted by law.
• Government representatives (including the Office for Human Research Protections) to complete
federal or state responsibilities
• The U.S. Food and Drug Administration
• The RESMED Foundation
• Your primary care physician if a medical condition that needs urgent attention is discovered
• Hospital or University representatives to complete Hospital or University responsibilities
• Information about your participation in this study may be documented in your health care records
and will be available to anyone with access to your health care record, including your health
insurance company. This information may also be released as part of a release of information
request.
• The last four digits of your social security number may be used in hospital or University systems
to track billing information for research procedures.
• Washington University’s Institutional Review Board (a committee that oversees the conduct of
research involving human participants) and the Human Research Protection Office. The
Institutional Review Board has reviewed and approved this study.
• Any report or article that we write will not include information that can directly identify you.
The journals that publish these reports or articles require that we share your information that was
collected for this study with others to make sure the results of this study are correct and help
develop new ideas for research. Your information will be shared in a way that cannot directly
identify you.
To help protect your confidentiality, we will have all paper documents locked in a filing cabinet in a
locked office of a member of the study team. We will keep all electronic documents on secured servers
that are password protected and have various state of the art firewall protections with frequent upgrades
of these protections. Access to these electronic research files will be restricted to members of the
research team and will be controlled by the principal investigator.
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required by U.S.
Law. This Web site will not include information that can identify you. At most, the Web site will
include a summary of the results. You can search this Web site at any time.
Are there additional protections for my health information?
Protected Health Information (PHI) is health information that identifies you. PHI is protected by federal
law under HIPAA (the Health Insurance Portability and Accountability Act). To take part in this
research, you must give the research team permission to use and disclose (share) your PHI for the study
as explained in this consent form. The research team will follow state and federal laws and may share
your health information with the agencies and people listed under the previous section titled, “How will
you keep my information confidential?”
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Once your health information is shared with someone outside of the research team, it may no longer be
protected by HIPAA.
The research team will only use and share your information as talked about in this form or as permitted or
required by law. When possible, the research team will make sure information cannot be linked to you
(de-identified). Once information is de-identified, it may be used and shared for other purposes not
discussed in this consent form. If you have questions or concerns about your privacy and the use of your
PHI, please contact the University’s Privacy Officer at 866-747-4975.
Although you will not be allowed to see the study information, you may be given access to your health
care records by contacting your health care provider.
If you decide not to sign this form, it will not affect
• your treatment or the care given by your health provider.
• your insurance payment or enrollment in any health plans.
• any benefits to which you are entitled.
However, it will not be possible for you to take part in the study.
If you sign this form:
• You authorize the use of your PHI for this research
• This authorization does not expire.
• You may later change your mind and not let the research team use or share your information
(you may revoke your authorization).
• To revoke your authorization, complete the withdrawal letter, found in the Participant section
of the Human Research Protection Office website at
https://hrpo.wustl.edu/participants/withdrawing-from-a-study/ or you may request that the
investigator send you a copy of the letter.
o If you revoke your authorization:
 The research team may only use and share information already collected for
the study.
 Your information may still be used and shared as necessary to maintain the
integrity of the research, for example, to account for a participant’s
withdrawal from the research study or for safety reasons.
 You will not be allowed to continue to participate in the study.

Can we contact you by email?
We would like to contact you by email for the purposes listed below. Some of these emails may contain
health information that identifies you.
•
•

Patient education
Appointment scheduling, which may contain PHI

Only the research team will have access to your email communications. We will only communicate by
email to send you the information listed above. If you have any questions or need to contact us for an
02/05/2020
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urgent or emergent situation, please contact the research team member identified at the top of this
document.
You should be aware that there are risks associated with sending your health information via email.
• There is always a risk that the message could be intercepted or sent to the wrong email
address. To avoid sending messages to the wrong email address, the first email we send you
will be a test message to ensure we have the correct email address.
• When using any computer you should be careful to protect your username and password.
Make sure you log-out before getting up from the computer.
• If you share a home computer with other family members, and do not want them to know you
are participating in this study make sure you provide an email address that only you can
access.
• Your employer will have access to any email communications sent or received on any
electronic devices used for work or through a work server.
Do you agree to allow us to send your health information via email?
_____ Yes

_____ No

Initials

Initials

IS BEING IN THIS STUDY VOLUNTARY?
Taking part in this research study is completely voluntary. You may choose not to take part at all. If
you decide to be in this study, you may stop participating at any time. Any data that was collected as
part of your participation in the study will remain as part of the study records and cannot be removed.
If you decide not to be in this study, or if you stop participating at any time, you won’t be penalized or
lose any benefits for which you otherwise qualify.
What if I decide to withdraw from the study?
You may withdraw by telling the study team you are no longer interested in participating in the study or
you may send in a withdrawal letter. A sample withdrawal letter can be found at
https://hrpo.wustl.edu/participants/withdrawing-from-a-study/ under Withdrawing from a Research
Study.
If you decide to leave the study early, we will ask you to return the home sleep monitor and aPAP
machines.
If you withdraw from the study we will ask your permission to continue to collect information from your
health care records. Should this occur we will ask you to sign a separate consent form before collecting
this information.
Will I receive new information about the study while participating?
If we obtain any new information during this study that might affect your willingness to continue
participating in the study, we’ll promptly provide you with that information.
02/05/2020
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Can someone else end my participation in this study?
Under certain circumstances, the investigator might decide to end your participation in this research
study earlier than planned. This might happen for no reason or because in our judgment it would not be
safe for you to continue, because funding for the research study has ended, because the sponsor has
decided to stop the research.
WHAT IF I HAVE QUESTIONS?
We encourage you to ask questions. If you have any questions about the research study itself, please
contact: Liz Wilson 314-454-5967. If you experience a research-related injury, please contact: Alex
Hincker at 314-362-2628.
If you have questions, concerns, or complaints about your rights as a research participant, please contact
the Human Research Protection Office 1-(800)-438-0445, or email hrpo@wustl.edu. General
information about being a research participant can be found on the Human Research Protection Office
web site, http://hrpo.wustl.edu. To offer input about your experiences as a research participant or to
speak to someone other than the research staff, call the Human Research Protection Office at the number
above.
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This consent form is not a contract. It is a written explanation of what will happen during the study if
you decide to participate. You are not waiving any legal rights by agreeing to participate in this study.
As a participant you have rights and responsibilities as described in this document and including:
• To be given enough time before signing below to weigh the risks and potential benefits and
decide if you want to participate without any pressure from the research team or others.
• To understand all of the information included in the document, have your questions answered,
and receive an explanation of anything you do not understand.
• To follow the procedures described in this document and the instructions of the research team to
the best of your ability unless you choose to stop your participation in the research study.
• To give the research team accurate and complete information.
• To tell the research team promptly about any problems you have related to your participation, or
if you are unable to continue and wish to stop participating in the research study.
Your signature indicates that this research study has been explained to you, that your questions have
been answered, and that you agree to take part in this study. You will receive a signed and dated copy
of this form.

Do not sign this form if today’s date is after $STAMP_EXP_DT.
__________________________________________
(Signature of Participant)

_______________________________
(Date)

____________________________________________
(Participant's name – printed)

Statement of Person Who Obtained Consent
The information in this document has been discussed with the participant or, where appropriate, with the
participant’s legally authorized representative. The participant has indicated that they understand the
risks, benefits, and procedures involved with participation in this research study.

__________________________________________
(Signature of Person who Obtained Consent)

_______________________________
(Date)

___________________________________________
(Name of Person who Obtained Consent - printed)
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University of Rochester / Strong Hospital - Birth weight nomogram
Local nomogram from 115,000 births in the nine-county Finger Lakes Region, 2004-2013. [60, 61]
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